The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression
Open accessAbstract
// Lekun Fang 1,* , Haoran Li 2,4,* , Lei Wang 1 , Jun Hu 1 , Tianru Jin 3 , Jianping Wang 1 , Burton B Yang 2,4 1 Guangdong Gastroenterology Institute, The Sixth Affiliated Hospital of Sun Yat-sen University, China 2 Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto 3 University Health Network, Toronto, Canada 4 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto * These authors contributed equally Correspondence: J Wang, email: // BB Yang, email: // Keywords : microRNA, stem cell, miR-17, colon cancer, drug resistance Received : November 19, 2013 Accepted : January 19, 2014 Published : January 19, 2014 Abstract Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, especially in Western countries. Although chemotherapy is used as an adjuvant or as a palliative treatment, drug resistance poses a great challenge. This study intended to identify biomarkers as predictive factors for chemotherapy. Patients and methods: By microarray analysis, we studied miRNAs expression profiles in CRC patient, comparing chemoresistant and chemosensitive groups. The miRNAs of interest were validated and the impact on clinical outcomes was assessed in a cohort of 295 patients. To search for potential targets of these miRNAs, tissue samples were subject to in situ hybridization and immunohistochemistry analysis. Colorectal adenocarcinoma cells were also used for in vitro experimentation, where cellular invasiveness and drug resistance were examined in miRNA-transfected cells. Results: The expression level of miRNA-17-5p was found increased in chemoresistant patients. Significantly higher expression levels of miR-17-5p were found in CRC patients with distant metastases and higher clinical stages. Kaplan-Meier analysis showed that CRC patients with higher levels of miR-17-5p had reduced survival, especially in patients who had previously received chemotherapy. Overexpression of miR-17-5p promoted COLO205 cell invasiveness. We found that PTEN was a target of miR-17-5p in the colon cancer cells, and their context-specific interactions were responsible for multiple drug-resistance. Chemotherapy was found to increase the expression levels of miR-17-5p, which further repressed PTEN levels, contributing to the development of chemo-resistance. Conclusions: MiR-17-5p is a predictive factor for chemotherapy response and a prognostic factor for overall survival in CRC, which is due to its regulation of PTEN expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, H., & Yang, B. B. (2012) · Oncotarget · doi:10.18632/oncotarget.810 · Cited by 117
Self-citation
Cited by
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Yang, C., Yuan, W., Yang, X., Li, P., Wang, J., Han, J., Tao, J., Li, P., Yang, H., Lv, Q., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0771-7 · Cited by 515
Self-citationData Normalization Strategies for MicroRNA Quantification
Schwarzenbach, H., da Silva, A. M., Calin, G., & Pantel, K. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.239459 · Cited by 468
Small non-coding RNA and cancer
Romano, G., Veneziano, D., Acunzo, M., & Croce, C. M. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx026 · Cited by 423
Metadata
- Authors
- Fang, L., Li, H., Wang, L., Hu, J., Jin, T., Wang, J., & Yang, B. B.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-01-19
- Volume
- 5
- Issue
- 10
- Pages
- 2974-2987
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1540008871
- Cited by
- 209
- References
- 1
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.